Exosomal PD-L1 in cancer and other fields: recent advances and perspectives

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Programmed cell death protein 1 (PD-1)/PD-1 ligand (PD-L1) signaling is crucial for tumor immune evasion.
• Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 have shown clinical success but face resistance in certain cancers.
• Interferon-gamma (IFN-γ) induces cancer cells to release exosomal PD-L1 (exoPD-L1), which can suppress anti-tumor immune responses.

Purpose of the Study:

• To review the role of PD-1/PD-L1 signaling and its reverse signaling in cancer.
• To summarize current cancer immunotherapies, focusing on PD-1/PD-L1 inhibitors.
• To explore the mechanisms, regulation, biomarker potential, and therapeutic targeting of exoPD-L1.

Main Methods:

• Literature review of PD-1/PD-L1 signaling and exoPD-L1.
• Analysis of exoPD-L1's role in immune suppression and immunotherapy response.
• Examination of methods for exoPD-L1 detection and quantification.
• Review of therapeutic strategies targeting exoPD-L1.

Main Results:

• PD-1/PD-L1 signaling is a key immunosuppressive mechanism in the tumor microenvironment.
• ExoPD-L1 contributes to immune evasion and is linked to resistance against anti-PD-1 therapy.
• ExoPD-L1 has potential as a biomarker and therapeutic target for enhancing cancer immunotherapy.

Conclusions:

• ExoPD-L1 plays a significant role in cancer immune evasion and response to immunotherapy.
• Targeting exoPD-L1 presents a promising strategy to overcome resistance and improve cancer treatment outcomes.
• ExoPD-L1's functions extend beyond cancer, indicating broader biological relevance.